정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 737 | Active, not recruiting | Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster | Covid19 | Biological: Placebo Biological: Inactivated vaccine booster Biological: mRNA vaccine booster Drug: Viral vector vaccine booster |
Phase 2 | Universidad del Desarrollo, Ministry of Health, Chile, University of Chile, Pontificia Universidad Catolica de Chile | OTHER | 534 | All | 18 Years | ELEAMs (Nursing Homes), Santiago, Chile Hospital de Urgencia Asistencia Publica, Santiago, Chile |
| 736 | Not yet recruiting | Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2 | COVID-19 | Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) | Phase 1 | Kafrelsheikh University, Foshan University Laboratory of Emerging Infectious Disease Institute of Translational Medicine The First Hospital of Jilin University China | OTHER | 24 | All | 18 Years ~ 80 Years | |
| 735 | Withdrawn | Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 | COVID-19 | Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2) | Not Applicable | The First Affiliated Hospital of Guangzhou Medical University | OTHER | 0 | All | 18 Years ~ 80 Years | GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China |
| 734 | Completed | Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 | COVID-19 | Drug: RhACE2 APN01 Drug: Physiological saline solution |
Phase 2 | Apeiron Biologics | INDUSTRY | 185 | All | 18 Years ~ 80 Years | Medizinische Universitat Innsbruck, Innsbruck, Austria Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria Medizinische Universitat Wien, Wien, Austria The National University Hospital, Rigshospitalet, Copenhagen, Denmark Herlev Gentofte Hospital, Herlev, Denmark Nordsjællands Hospital, Hillerød, Denmark Hvidovre Hospital, Hvidovre, Denmark Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany Regional State Budgetary Educational Institution "Clinical Hospital № 5, Barnaul", Barnaul, Russian Federation State Healthcare Institution "State Clinical Hspital № 15 named after O.M. Filatov", Moscow, Russian Federation Moscow State Budgetary Healthcare Institution "City Clinical Hospital №52 of Health Department of Moscow", Moscow, Russian Federation Moscow State Budgetary Healthcare Institution "N.V. Sklifosovsky Research Institute for Emergency Medicine of Health Department of Moscow", Moscow, Russian Federation Saint Petersburg SBHI City Hospital 38 named after N A Semashko, Pushkin, Russian Federation Federal State Budgetary Educational Institution of Higher Education "Ryazan State Medical University named after I.P. Pavlov" HD RF, Ryazan, Russian Federation Alexandrovskaya Hospital, Saint-Petersburg, Russian Federation Saint-Petersburg State Budget Healthcare Institution City Hospital 15, Saint-Petersburg, Russian Federation Federal State Budgetary Educational Institution of Higher Education " Saratov State Medical University named after V.I. Razumovsky" HD RF, Saratov, Russian Federation Regional State Budgetary Healthcare Institution "Clinical Hospital №1", Smolensk, Russian Federation State budgetary institution of Healthcare of Tver region "Regional clinical hospital", Tver, Russian Federation Yaroslavl Regional Clinical Hospital for Military Veterans - International Centre for Gerontological Problems "Healthy Ageing", Yaroslavl, Russian Federation Cambridge University Hospitals NHS Trust/University of Cambridge, Cambridge, United Kingdom |
| 733 | Recruiting | Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients | COVID-19 | Drug: GIGA-2050 | Phase 1 | GigaGen, Inc. | INDUSTRY | 18 | All | 18 Years | Icahn School of Medicine at Mount Sinai, New York, New York, United States |
| 732 | Active, not recruiting | Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old) | Coronavirus | Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group Biological: Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group |
Phase 1 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | INDUSTRY | 50 | All | 60 Years | Hunan Provincial Center for Disease Control and Prevention, Xiangtan, Changsha, China |
| 731 | Recruiting | Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old) | Coronavirus | Biological: Recombinant new coronavirus vaccine (CHO cell) group Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group |
Phase 1 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | INDUSTRY | 75 | All | 3 Years ~ 17 Years | Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China |
